Morgan Stanley Aptorum Group LTD Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.42 - $11.7 $1,330 - $37,053	-3,167 Reduced 3.74%	81,400 $44,000
Q3 2022 Nov 14, 2022	SELL	$1.14 - $12.9 $3,115 - $35,255	-2,733 Reduced 3.13%	84,567 $97,000
Q2 2022 Oct 27, 2022	BUY	$0.95 - $1.67 $6,840 - $12,024	7,200 Added 8.99%	87,300 $120,000
Q2 2022 Aug 15, 2022	BUY	$0.95 - $1.67 $6,840 - $12,024	7,200 Added 8.99%	87,300 $120,000
Q1 2022 Oct 27, 2022	SELL	$1.22 - $2.28 $8,784 - $16,416	-7,200 Reduced 8.25%	80,100 $134,000
Q1 2022 May 13, 2022	BUY	$1.22 - $2.28 $29,716 - $55,536	24,358 Added 43.7%	80,100 $134,000
Q4 2021 Feb 14, 2022	BUY	$1.5 - $2.64 $30,363 - $53,438	20,242 Added 57.02%	55,742 $84,000
Q3 2021 Nov 15, 2021	BUY	$2.39 - $3.22 $84,845 - $114,310	35,500 New	35,500 $91,000

Ticker APM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,265,500
Market Cap $16.4M
Description
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.